

**From:** avakado Media <publications@avakado.eu>  
**Sent:** Friday, February 17, 2012 9:34 AM  
**To:** Hanchett, James (DPH)  
**Subject:** Toms Top Ten this week Biogen Idec BASF and Evotec

Problems reading this email? [View in a browser](#)



Click on the arrow or [click here](#) to listen

February 17, 2012:

- [Biogen Idec to acquire biopharma company Stromedix](#)
- [PhRMA says US budget proposals threaten biopharma prospects](#)
- [FDA approves Merck & Co glaucoma treatment](#)
- [BASF to invest \\$33 million in plant biotech R&D facilities at RTP](#)
- [Blockbuster biologics patent expiries to create strong market opportunity](#)
- [Endeavour increases chemical product range through AKL partnership](#)
- [New York Genome Center launches Alzheimer's whole genome initiative](#)
- [Evotec and IR Pharma form discovery alliance in respiratory diseases](#)
- [Chemical distributor Brenntag opens Indian head office](#)
- [FDA requests additional data from Novartis for expanded use of diphtheria vaccine](#)

Brought to you by:



Tom's Top Ten sponsored by:



This email was sent from avakado Ltd.  
To stop receiving further emails, please reply to this message and include unsubscribe in the subject line.  
avakado Limited is a company registered in England and Wales. Company number 04186087. VAT Registration Number:GB783470408

#### UNSUBSCRIBE INFORMATION

This email was sent to james.hanchett@state.ma.us, by avakado Media.

[Opt-out of any future messages here.](#)

We will respect your decision to receive no further emails from us.

